India's pharma exports cross US$ 30 billion: Commerce Secretary Mr. Rajesh Agrawal
- IBEF
- December 19, 2025
The Indian pharmaceutical industry has achieved a record Rs. 2.72 lakh crore (US$ 30 billion) in exports, indicating sustained global demand for Indian vaccines, generic medicines, and other therapeutic products. According to Commerce Secretary Mr. Rajesh Agrawal, this export performance reflects the underlying strength of India’s pharmaceutical sector and its continued role as a key supplier to international markets, particularly regulated and semi-regulated economies. The growth in exports has been supported by enhanced production capacities, competitive pricing, adherence to high-quality standards, and strong regulatory compliance demonstrated by Indian pharmaceutical manufacturers.
According to Mr. Rajesh Agrawal, the milestone of achieving Rs. 2.72 lakh crore (US$ 30 billion) worth of drugs exported from India is indicative of steady growth in shipments of many different types of products, including formulations, bulk drugs, vaccines, etc. The increase in export value also demonstrates an increasing integration of India's pharmaceutical industry into the world's healthcare supply chain. The growing contribution of India's pharmaceutical sector to the country's foreign exchange earnings and the development of a diverse export strategy for this sector have allowed for reduced impacts for this industry during cyclical downturns in specific geographic regions. Continued demand from both traditional and emerging markets has supported this growth trend. The ongoing evolution of global healthcare will create increased opportunities for Indian manufacturers to leverage their capacity as manufacturers and quality assurance providers to further improve their performance in exports. Overall, pharmaceutical exports demonstrate that India is becoming a trusted and dependable partner in helping meet the increasing demand for globally needed healthcare while contributing to economic growth through increased trade.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.
Partners
